The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition (Q28572346)

31 January 2017

title

The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition (English)

1 reference

31 January 2017

0 references

T. Kino

1

1 reference

31 January 2017

K. C. Rice

series ordinal

2

1 reference

31 January 2017

G. P. Chrousos

series ordinal

3

1 reference

31 January 2017

publication date

1 May 2007

1 reference

European Journal of Clinical Investigation

31 January 2017

published in

1 reference

31 January 2017

volume

37

1 reference

31 January 2017

issue

5

1 reference

31 January 2017

page(s)

425–433

1 reference

Role of Peroxisome Proliferator-Activated Receptors in Inflammation Control

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01796.X

Transcriptional repression of atherogenic inflammation: modulation by PPARdelta

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01796.X

Principles of interleukin (IL)-6-type cytokine signalling and its regulation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01796.X

The glucocorticoid receptor and the orphan nuclear receptor chicken ovalbumin upstream promoter-transcription factor II interact with and mutually affect each other's transcriptional activities: implications for intermediary metabolism

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01796.X

PPAR delta: a dagger in the heart of the metabolic syndrome

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2007.01796.X

PPARs and the complex journey to obesity

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

PPARs: transcriptional effectors of fatty acids and their derivatives

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Reviews: current topicsrole of nuclear receptors in the regulation of gene expression by dietary fatty acids (review)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

PPARs: therapeutic targets for metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Nrf2, a multi-organ protector?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Cytokine dysregulation, inflammation and well-being.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

IL-6 in autoimmune disease and chronic inflammatory proliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Interleukin-6 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

The role of IL-6 type cytokines and their receptors in bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Interleukin-6: from basic science to medicine--40 years in immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha1-antichymotrypsin expression in human cortical astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Acute-Phase Response Factor, a Nuclear Factor Binding to Acute-Phase Response Elements, is Rapidly Activated by Interleukin-6 at the Posttranslational Level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

A Short and Efficient Synthesis of the Pharmacological Research Tool GW501516 for the Peroxisome Proliferator-Activated Receptor δ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

G protein beta interacts with the glucocorticoid receptor and suppresses its transcriptional activity in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

The Smad6-histone deacetylase 3 complex silences the transcriptional activity of the glucocorticoid receptor: potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Immunomodulatory therapies in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

Transcriptional inactivation of STAT3 by PPARgamma suppresses IL-6-responsive multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2362.2007.01796.X

10.1111/J.1365-2362.2007.01796.X

21 January 2018

Identifiers

DOI

1 reference

31 January 2017

1 reference